Ozempic vs Wegovy vs Mounjaro in Bali: A Doctor-Supervised Comparison

GLP-1 Medication is one of the effective medically supervised weight management therapies.

Ozempic vs Wegovy vs Mounjaro: A Doctor-Supervised Comparison for Patients in Bali

GLP-1 medications have rearranged the conversation around weight management more profoundly than any drug class in the past 50 years. Semaglutide (sold as Ozempic for diabetes and Wegovy for weight management) and tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight management) have produced weight-loss results in clinical trials that simply weren't achievable with diet, exercise, or previous pharmacological options. For patients who've tried everything else, this class of medications offers something genuinely new.

At SŌMA Aesthetics & Longevity Club in Uluwatu, Bali, we've been running doctor-supervised GLP-1 weight management programs since 2024. This article is a plain-English comparison for patients considering these medications: how they differ, what the evidence shows, and how our medical supervision model addresses the safety concerns that have become increasingly evident with unregulated GLP-1 sources.

The mechanism — GLP-1 receptor agonists, explained

Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone released by your gut after eating. It has several metabolic effects: it signals satiety to the brain, slows gastric emptying (so food stays in your stomach longer), reduces appetite, and stimulates insulin release from the pancreas while suppressing glucagon. GLP-1 receptor agonists are synthetic peptides that mimic this hormone, with modifications that prolong their half-life in the bloodstream far beyond that of natural GLP-1 (which is broken down in minutes).

Semaglutide (the active molecule in both Ozempic and Wegovy) is a long-acting GLP-1 receptor agonist. Tirzepatide (Mounjaro/Zepbound) is a dual agonist — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual mechanism in tirzepatide produces additional metabolic effects and, in head-to-head trial comparison, greater weight reduction than semaglutide alone.

The clinical evidence — what the trials actually showed

The evidence base for GLP-1 weight management is substantial and published in the highest-tier medical journals.

Semaglutide (Wegovy): The STEP (Semaglutide Treatment Effect in People with obesity) trial program was published in The New England Journal of Medicine. The landmark STEP 1 trial (Wilding et al, NEJM 2021; 384:989-1002) enrolled 1,961 adults with BMI ≥30 or ≥27 with weight-related comorbidities. Participants on semaglutide 2.4mg weekly lost an average of 14.9% of body weight at 68 weeks, versus 2.4% in the placebo group. More than 86% of participants lost at least 5% of body weight; approximately one-third lost more than 20%.

Tirzepatide (Mounjaro/Zepbound): The SURMOUNT trial program, published in NEJM. SURMOUNT-1 (Jastreboff et al, NEJM 2022; 387:205-216) enrolled 2,539 adults with BMI ≥30 or ≥27 with weight-related comorbidities. Participants on the highest dose tirzepatide (15mg weekly) lost an average of 20.9% of body weight at 72 weeks, versus 3.1% in the placebo group. Approximately 57% achieved ≥20% weight loss.

Direct comparison: The SURMOUNT-5 trial (published 2025) directly compared tirzepatide against semaglutide at the highest approved doses in adults with obesity without diabetes, showing significantly greater weight reduction with tirzepatide. The tirzepatide advantage was approximately 6-8 percentage points of total body weight lost over the 72-week follow-up.

For context: no previous non-surgical weight management intervention has reliably produced 15-20% body weight reduction in the majority of recipients. These are outcomes that previously required bariatric surgery.

The three medications — head-to-head

Feature	Ozempic	Wegovy	Mounjaro
Active molecule	Semaglutide	Semaglutide	Tirzepatide
Receptor target	GLP-1	GLP-1	GLP-1 + GIP (dual)
Manufacturer	Novo Nordisk	Novo Nordisk	Eli Lilly
FDA-approved for	Type 2 diabetes	Weight management (BMI ≥30 or ≥27 with comorbidities)	Type 2 diabetes (Zepbound: weight management)
Typical dose range	0.25mg → 2.0mg weekly	0.25mg → 2.4mg weekly	2.5mg → 15mg weekly
Average weight loss at 68-72 weeks	~12-14% (off-label use)	~15% (STEP trial)	~20% (SURMOUNT trial)
Dosing frequency	Once weekly injection	Once weekly injection	Once weekly injection
Typical side effects	Nausea, constipation, diarrhoea (usually transient, dose-dependent)	Same profile as Ozempic	Same profile; dual mechanism can produce slightly more GI effects at higher doses

Ozempic vs Wegovy — practical difference

The same molecule (semaglutide) in the same delivery format (weekly subcutaneous injection). Ozempic is licensed for type 2 diabetes with doses up to 2.0mg weekly.

Wegovy is licensed for weight management with doses up to 2.4mg weekly. In practice, "using Ozempic for weight loss" means off-label use of a diabetes-licensed product. In many markets (including Indonesia, the UK, Singapore, and throughout Europe), Wegovy availability has historically been limited, which has driven substantial off-label Ozempic prescribing for weight management.

Clinically, the medications do the same thing. The regulatory difference matters for formal weight-management indications and sometimes for insurance reimbursement; it doesn't reflect a meaningful clinical difference in outcomes when dosed appropriately.

Mounjaro (tirzepatide) — the dual-agonist advantage

Tirzepatide's dual mechanism produces consistently greater weight loss in trial comparisons. For patients who've failed semaglutide (insufficient weight loss, plateau at target doses, or intolerance), tirzepatide is increasingly the second-line option. For patients starting fresh with the highest likelihood of significant weight reduction as the goal, tirzepatide is arguably the first-line choice — pending cost, availability, and individual patient factors.

Trade-offs: tirzepatide's higher potency can mean slightly more pronounced GI side effects during titration, particularly nausea during the 2.5mg → 5mg → 7.5mg → 10mg → 15mg escalation. Most patients tolerate this with appropriate dose titration and pacing.

The safety question — why doctor supervision matters

GLP-1 medications are extremely effective. They are also real medications with real risks that benefit substantially from proper medical supervision.

Known adverse effects documented in clinical trials:

• Gastrointestinal: Nausea (most common, especially during dose titration), vomiting, diarrhoea, constipation. Usually transient, but can be severe enough in some patients to require dose reduction or discontinuation.

• Pancreatitis: Rare but serious. Patients with a personal history of pancreatitis should generally not use these medications.

• Gallbladder complications: Increased risk of cholelithiasis and cholecystitis, particularly with rapid weight loss.

• Medullary thyroid carcinoma risk: GLP-1 agonists are contraindicated in patients with personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

• Acute kidney injury: Risk is elevated in dehydrated patients, particularly during episodes of severe nausea/vomiting.

• Hypoglycaemia: Particularly relevant in patients with diabetes on concurrent insulin or sulphonylurea therapy.

• Loss of lean mass: Rapid weight loss can reduce both muscle and fat mass. Resistance training and adequate protein intake during treatment are essential.

The specific risks of unsupervised GLP-1 use:

Across 2024-2025, European and Asian regulatory authorities have documented increasing safety incidents associated with unregulated GLP-1 sources. The specific patterns include: counterfeit products (contents not matching the label), compounded semaglutide from non-pharmacy sources (no batch quality control), telemedicine-only prescribing without adequate medical assessment, and absence of the contraindication screening and monitoring that proper clinical use requires.

A patient using GLP-1 without medical supervision may miss: contraindication screening (thyroid cancer history, pancreatitis history), baseline metabolic assessment, dose titration management, monitoring for pregnancy (GLP-1 medications require discontinuation before conception), monitoring for side effects requiring intervention, and crucially, guidance on protein intake and resistance training to preserve lean mass during weight loss.

The SŌMA program structure

Our Weight Management Program is designed to address safety gaps in unsupervised GLP-1 use while making the medications accessible at affordable prices.

Initial assessment (Day 1)

• Comprehensive medical history, including screening for contraindications (medullary thyroid cancer history, MEN2, pancreatitis, severe gastroparesis, pregnancy planning)

• Physical examination, BMI and body composition analysis

• Comprehensive metabolic bloodwork: HbA1c, fasting glucose, lipid panel, liver function, kidney function, TSH, vitamin D, B12, ferritin

• Medication selection discussion based on clinical profile, goals, availability, and budget

• Baseline measurements and photography for progress tracking

  
  

The initial consultation is conducted by Dr Ary Wulandari Sp.D.V.E, Dr Andrew Uidjaja M. Biomed, Dr Yuan, Dr Nadim M.Biomed with all protocols designed and supervised under Dr. Shirley's medical direction.

Treatment phase (ongoing)

• Medication prescribed and dispensed only through authorised Indonesian pharmacy channels — no compounded or unregulated sources

• Dose titration protocol aligned with manufacturer guidance (Ozempic/Wegovy: start 0.25mg, escalate monthly; Mounjaro: start 2.5mg, escalate monthly)

• Monthly clinical check-ins (in-person for local patients; WhatsApp video for international patients) to assess tolerance, side effects, weight trajectory

• Nutritional guidance emphasising adequate protein intake (target 1.2-1.6g per kg body weight) to preserve lean mass

• Resistance training referral/guidance to maintain muscle during weight loss

  
  

Monitoring phase (quarterly)

• Repeat metabolic bloodwork at 3 months to assess trajectory

• Dose adjustment based on response and tolerance

• Body composition re-assessment

• Maintenance planning as goals are achieved

Pricing — what the program actually costs at SŌMA

2026 SŌMA pricing for GLP-1 weight management:

• Initial Weight Management Consultation: IDR 1,200,000 (approximately USD 72, SGD 110, GBP 57). If you decide to go ahead with a 2-month plan, the consultation fees will be included.

• Comprehensive Metabolic Blood Panel: IDR 2,500,000 (approximately USD 150, SGD 210, GBP 118)

• Ozempic (semaglutide) — monthly: from IDR 4,500,000 (titration doses 0.25-1mg) to IDR 6,500,000 (maintenance 2mg) — approximately USD 270-390 / SGD 380-550 / GBP 215-310 prescribed for diabetic patients

• Wegovy (semaglutide 2.4mg) — monthly: IDR 7,500,000 (approximately USD 450 / SGD 635 / GBP 355)

• Mounjaro (tirzepatide) — monthly: IDR 6,800,000-8,500,000 depending on dose (approximately USD 410-510 / SGD 575-720 / GBP 325-405)

All medications are BPOM-registered and sourced through authorised official Indonesian distributors only.

Comparative international pricing (2026 published rates)

Market	Ozempic monthly	Wegovy monthly	Mounjaro monthly
Australia (private)	AUD 400-500	AUD 320-500	AUD 550-720
Singapore (private)	SGD 850-1,400	SGD 1,500-2,200	SGD 1,400-2,500
USA (cash pay, no insurance)	USD 900-1,300	USD 1,350-1,800	USD 1,100-1,700
UK (private)	GBP 200-350	GBP 300-450	GBP 250-500
Hong Kong (licensed clinics)	HKD 3,000 - 6,000	HKD 2,680 - 4,500	HKD 4,500 - 9,000
Dubai /UAE (private)	AED 900 - 2,200	AED 2,000 - 2,800	AED 1,500 - 2,600
Germany (private)	EUR 250-450	EUR 300-500	EUR 350-600
SŌMA Bali	USD 270-390	USD 450	USD 410-510

*Wegovy is not yet formally approved in the UAE; prices shown reflect off-label supply through licensed clinics or compassionate-use imports. Availability is limited and varies by provider.

The price advantage is substantial across most comparison markets, especially when combined with the integrated medical supervision model. Notes on methodology:

Savings percentages compare the midpoint of each country's published private-market pricing against SŌMA's published rates, converted at April 2026 exchange rates for equivalence.

Savings reflect pure medication-cost differences only. They do not factor in the additional value of SŌMA's included comprehensive bloodwork, monthly clinical monitoring, and doctor-led supervision — all typically charged separately in other markets.

"Parity" entries indicate markets where pure medication costs are broadly comparable. For patients in these markets, SŌMA's value proposition shifts to integrated program value (longevity protocols, aesthetic treatment consolidation, comprehensive metabolic monitoring) rather than drug-cost savings alone.

Who benefits most from doctor-supervised GLP-1 therapy?

Based on current clinical guidelines and our patient experience:

Strong indication:

• BMI ≥30 (obesity) without active contraindications

• BMI ≥27 (overweight) with weight-related comorbidities such as hypertension, dyslipidaemia, type 2 diabetes, sleep apnoea, or fatty liver disease

• Patients who have attempted weight management through diet and exercise without sustained results

• Patients who have plateaued with other weight management interventions

Relative indication (clinical judgement):

• BMI 25-27 with specific metabolic drivers (pre-diabetes, insulin resistance, PCOS)

• Patients preparing for weight-related surgery or other medical interventions

• Patients with specific body composition goals beyond BMI criteria

  
  

Not indicated or contraindicated:

• Pregnancy, breastfeeding, or pregnancy planning within next 2 months

• Personal or family history of medullary thyroid cancer or MEN2 syndrome

• Personal history of pancreatitis

• Active severe gastroparesis or severe gastrointestinal disease

• BMI below 25 (cosmetic use for body contouring in normal-weight individuals is not appropriate)

• Eating disorder history — GLP-1 use can be problematic for patients with restrictive eating patterns

Frequently asked questions

Is Ozempic "better" for weight loss than Wegovy?

The active molecule is identical (semaglutide). Ozempic is licensed for diabetes with doses up to 2.0mg weekly; Wegovy is licensed for weight management with doses up to 2.4mg weekly. In clinical trials, the weight loss effects scale with dose — patients on 2.4mg semaglutide (Wegovy) lose slightly more weight than those on 2.0mg (Ozempic). In practical terms, both deliver significant weight loss; Wegovy is the formally weight-indicated option when the dose specificity matters.

Should I start on Mounjaro first to get maximum weight loss?

The SURMOUNT trial data supports tirzepatide as producing greater weight loss than semaglutide in direct head-to-head comparison. For patients prioritising maximum weight reduction, tirzepatide (Mounjaro) is a reasonable first-line choice — pending clinical assessment, contraindication screening, and tolerance of the dose titration. That said, semaglutide also produces clinically significant weight loss (14-15% on average); patient-specific factors including cost, availability, and individual response often guide the decision.

What happens when I stop the medication?

Weight regain is the most challenging aspect of GLP-1 therapy. Published data (STEP 1 extension studies) shows that after medication discontinuation, patients regain approximately two-thirds of their weight loss over 12 months. This is not a reflection of treatment failure — it's a reflection of obesity being a chronic condition requiring ongoing management, like hypertension or diabetes. At SŌMA, we frame GLP-1 therapy as long-term maintenance for most patients, not a short-term intervention. Planned discontinuation requires specific strategies: gradual dose tapering, intensive nutrition and exercise coaching, and transition protocols that preserve results where possible.

Can I use GLP-1 medications alongside other SŌMA longevity protocols?

Yes, and many of our patients do. GLP-1 therapy integrates well with: comprehensive longevity protocols (given the metabolic benefits beyond weight loss — improved HbA1c, lipid profile, blood pressure, and inflammatory markers); hormone optimisation (particularly in perimenopausal and post-menopausal women where weight management is more difficult); NAD+ IV therapy; and body sculpting treatments. The combination often produces better outcomes than any individual intervention.

What if I'm not overweight but want to use GLP-1 for body contouring?

We don't prescribe GLP-1 medications for cosmetic weight loss in normal-weight individuals. The medical risk-benefit doesn't support this use, and it's not consistent with the evidence-based clinical framework we practise. For patients within normal BMI who want body contouring, we offer EMS body sculpting, Mesolipo injection therapy, and other localised approaches that target specific areas without systemic medication.

What about compounded semaglutide or peptide-source GLP-1?

We don't use compounded semaglutide, peptide-source GLP-1 products, or "research chemical" GLP-1 variants. Every GLP-1 medication dispensed at SŌMA is the authentic branded product (Ozempic, Wegovy, or Mounjaro) sourced through authorised Indonesian pharmacy channels with BPOM registration. This is a non-negotiable clinical standard. The patient-safety incidents documented across compounded GLP-1 sources — including contamination, incorrect dosing, and contents not matching labelling — are exactly what medical supervision exists to prevent.

Research methodology and data sources

Clinical evidence cited in this article was compiled from peer-reviewed publications indexed on PubMed, with search cut-off April 2026. Primary sources include: Wilding et al (New England Journal of Medicine 2021; 384:989-1002) — STEP 1 trial for semaglutide in obesity without diabetes; Jastreboff et al (NEJM 2022; 387:205-216) — SURMOUNT-1 trial for tirzepatide; SURMOUNT-5 direct comparison of tirzepatide vs semaglutide (2025 publication); plus secondary sources on GLP-1 adverse effect profiles, contraindication guidance (FDA prescribing information for Ozempic, Wegovy, Mounjaro), and post-discontinuation weight regain data.

Comparative international pricing was compiled in April 2026 from publicly published clinic pricing pages across Singapore, the USA, the UK, and Germany, and from recent industry analysis of GLP-1 cash-pay pricing in each market. Currency conversions use April 2026 exchange rates. SŌMA pricing reflects published 2026 rates in Indonesian Rupiah (IDR), exclusive of the 11% Indonesian government tax.

This article is published for educational purposes and does not constitute individual medical advice. GLP-1 receptor agonists are prescription medications with specific indications, contraindications, and monitoring requirements. Consultation with a qualified physician for contraindication screening, baseline assessment, prescription, and ongoing monitoring is essential before and during GLP-1 therapy. Individual results vary based on baseline characteristics, dose, adherence, and concurrent lifestyle interventions.

Considering GLP-1 weight management in Bali? Book a free consultation via WhatsApp. Dr. Boy Ardi Rohanda Sp.D.V.E, Dr. Ary Wulandari Sp.D.V.E, or Dr. Nadim M.Biomed will conduct your initial assessment, arrange appropriate bloodwork, and recommend the specific medication, dose, and monitoring schedule appropriate for your clinical profile — with transparent pricing in your preferred currency before you commit.